J.P. Morgan analyst Jessica Fye maintained a Buy rating on Ascendis Pharma (ASND – Research Report) today and set a price target of $167.00.

In a report released on January 27, Jessica Fye from J.P. Morgan maintained a Buy rating on Intra-Cellular Therapies (ITCI – Research Report), ...

These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...

JPMorgan analyst Jessica Fye adjusted the price target for Ascendis Pharma (NASDAQ:ASND), a $7.74 billion biotech company, to $167.00, a slight increase from the previous $165.00, while reiterating ...

Great. Good morning, everyone. Welcome. I'm Jess Fye, Biotech Analyst at J.P. Morgan. We're kicking off the 43rd Annual Healthcare Conference this morning, and I couldn't be more delighted to ...

Image: Supplied Lendo, the leading debt crowdfunding platform in Saudi Arabia, announced securing a $690 million (SAR 2.6 billion) warehouse facility led by J.P. Morgan. Supported by Fintech Saudi, ...

J.P. Morgan Payments, the payments arm of banking giant JPMorgan Chase & Co., is blazing its own path with two new payment terminals, both proprietary to the payment service. Announced Monday, the J.P ...

This can increase the total return potential for investors. The research team at J.P. Morgan is out with the firm’s 2025 Year Ahead Best Idea list, and we found five companies that look like ...

JP Morgan posted stronger-than-expected fourth quarter earnings Wednesday as dealmaking help boost the group's bottom line and offset an overall slide in net interest income tied to lower Federal ...

San Francisco Police cancel time off requests to increase security at the J.P. Morgan Healthcare Conference after the recent murder of UnitedHealth Group CEO Brian Thompson. In the wake of the murder ...

The Westin St. Francis Hotel in Union Square will once again be host for one of the biggest conventions in the city--the J.P. Morgan Healthcare Conference. The conference includes global industry ...